Evidence map›Paper›PMID 39185173›Full record

ArticlebioRxiv : the preprint server for biology2024

Identification of biomarkers for COVID-19 associated secondary hemophagocytic lymphohistiocytosis.

Susan P Canny, Ian B Stanaway, Sarah E Holton, Mallorie Mitchem, Allison R O'Rourke, Stephan Pribitzer, Sarah K Baxter, Mark M Wurfel, Uma Malhotra, Jane H Buckner and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Susan P CannyCenter for Fundamental Immunology, Benaroya Research Institute, Seattle, WA.ORCID 0000-0002-1762-6718
Ian B StanawayKidney Research Institute and Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA.
Sarah E HoltonDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA.
Mallorie MitchemCenter for Translational Immunology, Benaroya Research Institute, Seattle, WA.
Allison R O'RourkeCenter for Fundamental Immunology, Benaroya Research Institute, Seattle, WA.
Stephan PribitzerCenter for Systems Immunology, Benaroya Research Institute, Seattle, WA.
Sarah K BaxterDepartment of Pediatrics, University of Washington, Seattle, WA.
Mark M WurfelDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA.
Uma MalhotraDepartment of Infectious Disease, Virginia Mason Medical Center, Seattle, WA.
Jane H BucknerCenter for Translational Immunology, Benaroya Research Institute, Seattle, WA.
Pavan K BhatrajuDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA.
Eric D MorrellDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA.
Cate SpeakeCenter for Interventional Immunology, Benaroya Research Institute, Seattle, WA.
Carmen MikacenicDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA.
Jessica A HamermanCenter for Fundamental Immunology, Benaroya Research Institute, Seattle, WA.

Funding

Technology Development Project - Increasing the complexity of ex vivo human airway models for studying immune response to viral infectionU19AI142733 · NIAID · JACKSON LABORATORY · PI Julia Oh · 2019 to 2026
$23.1M
RESPIRATORY RESEARCH TRAINING PROGRAMT32HL007287 · NHLBI · UNIVERSITY OF WASHINGTON · PI Kristina Anne Crothers, David J. Horne · 1985 to 2026
$16.7M
BCAP regulation of TLR7/9 signaling in LupusR01AI150178 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI HAMERMAN, JESSICA A · 2020 to 2024
$3.7M
Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS)R01HL149676 · NHLBI · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI MIKACENIC, CARMEN R · 2020 to 2024
$3.0M
Defining the role of IRF5 in inflammatory hemophagocyte differentiationF32HL156516 · NHLBI · UNIVERSITY OF WASHINGTON · PI CANNY, SUSAN PRISCILLA · 2021 to 2021
$72k
NHLBI NIH HHS F32 HL156516NHLBI NIH HHS R01 HL149676NHLBI NIH HHS T32 HL007287NIAID NIH HHS R01 AI150178NIAID NIH HHS U19 AI142733
6 · The paper itself

Abstract

objectivesWe aimed to define and validate novel biomarkers that could identify individuals with COVID-19 associated secondary hemophagocytic lymphohistiocytosis (sHLH) and to test whether fatalities due to COVID-19 in the presence of sHLH were associated with specific defects in the immune system.

designIn two cohorts of adult patients presenting with COVID-19 in 2020 and 2021, clinical lab values and serum proteomics were assessed. Subjects identified as having sHLH were compared to those with COVID-19 without sHLH. Eight deceased patients defined as COVID-sHLH underwent genomic sequencing in order to identify variants in immune-related genes.

settingTwo tertiary care hospitals in Seattle, Washington (Virginia Mason Medical Center and Harborview Medical Center). PATIENTS: 186 patients with COVID-19.

interventionsNone. MEASUREMENTS AND MAIN

resultsNine percent of enrolled COVID-19 subjects met our defined criteria for sHLH. Using broad serum proteomic approaches (O-link and SomaScan), we identified three biomarkers for COVID-19 associated sHLH (soluble PD-L1, TNF-R1, and IL-18BP), supporting a role for proteins previously associated with other forms of sHLH (IL-18BP and sTNF-R1). We also identified novel biomarkers and pathways of COVID-sHLH, including sPD-L1 and the syntaxin pathway. We detected variants in several genes involved in immune responses in individuals with COVID-sHLH, including in

conclusionsBiomarkers of COVID-19 associated sHLH, such as soluble PD-L1, and pathways, such as the syntaxin pathway, and variants in immune genes in these individuals, suggest critical roles for the immune response in driving sHLH in the context of COVID-19.

Identifiers

PMID39185173
PMCPMC11343163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.